NHS Requirements for Weight Loss Injections: What You Actually Need to Qualify

Step 1: Understanding which medicine the NHS is offering and why

The NHS in England can now offer two injectable weight management medicines. Tirzepatide, sold as Mounjaro and made by Eli Lilly, was recommended by NICE in December 2024 (TA1026) and is being rolled out in phases through primary care. Semaglutide (Wegovy, by Novo Nordisk) was recommended by NICE in 2023 (TA875) and is available via specialist weight management services, though waiting lists are substantial in most areas.

Both are Prescription-Only Medicines. Neither can be dispensed on the NHS without a formal prescription following clinical review. The NICE recommendations set out the conditions under which the NHS will fund them, and those conditions are deliberately staged, starting with the patients whose need is most urgent. You can read the full criteria in NICE's appraisal of tirzepatide (TA1026).

It is also worth knowing that the criteria differ depending on which medicine you are being considered for. Tirzepatide's NICE recommendation covers a broader NHS rollout through GP practices from April 2026 onwards; semaglutide under TA875 sits within specialist services. Mixing them up is one of the most common sources of confusion when people research this topic.

Step 2: The phased BMI and comorbidity criteria for tirzepatide on the NHS

The NHS England rollout of tirzepatide follows a structured timetable. From June 2025, adults with a BMI of 40 or above and four or more of the five qualifying conditions became eligible. That first cohort is already being seen in participating GP practices. From around June 2026, eligibility expanded to include adults with a BMI between 35 and 39.9, again requiring four or more qualifying conditions, a significant widening that brings a much larger group into scope.

The five qualifying conditions are: high blood pressure, dyslipidaemia (raised cholesterol or triglycerides), obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. Reaching March 2027, the threshold drops further to BMI 40 or above with three or more conditions. If your background is South Asian, Chinese, Middle Eastern, Black African or African-Caribbean, UK guidance applies BMI thresholds that are 2.5 kg/m² lower throughout each phase. The NHS BMI thresholds for weight loss injections page covers this in more detail.

One practical note: from April 2026, GP practices can prescribe under the new contract, but participation is optional. Your practice may not yet be signed up, even if you meet the criteria. Every NHS patient must also take part in supported lifestyle and dietary input alongside treatment, that wraparound care is a condition of prescribing, not optional.

Step 3: What to do if you do not meet the NHS criteria yet

A large number of people fall just outside the current phase, perhaps a BMI of 33, or only two of the five conditions, or a GP surgery that has not yet joined the scheme. That gap is real, and it is why private prescriptions for weight loss injections have grown significantly since NICE published its recommendations.

The licensed private eligibility criteria, set out in the medicines' Summary of Product Characteristics, are broader. Adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition, may be suitable for a private prescription following clinical assessment. A prescriber assesses the whole picture (medical history, current medications, whether these medicines are appropriate for you) and BMI alone is never the sole deciding factor. Type 2 diabetes and weight loss injections on the NHS have their own eligibility pathway, which this dedicated page explains.

For context on what private treatment costs (and what a legitimate price should include) the guide to weight loss injection costs sets out the market honestly. Eli Lilly raised Mounjaro's UK list price significantly from September 2025, so prices reported before that date may no longer reflect what you will pay.

Step 4: Verifying that any route you use is legitimate

Whichever route you take, the medicine should come from a pharmacy registered with the GPhC. Counterfeits are a documented problem: the MHRA has warned publicly about fake weight loss pens (some containing insulin rather than the stated medicine) and enforcement in 2025 resulted in roughly 20 million doses seized from illegal supply chains. Report any suspect seller at the MHRA's Yellow Card scheme.

You can verify any online pharmacy at the GPhC register. At nume, our GPhC premises registration number is 9012878, you can confirm it directly on the GPhC register. Every consultation is reviewed by a GPhC-registered Independent Prescriber on the day it is submitted. Your medicine is dispensed through the licensed UK supply chain and, if you need it quickly, we offer weight loss injections with next day delivery, tracked by DPD, in plain packaging. The pen goes straight in the fridge when it arrives (next to whatever else is on the top shelf) and from there your prescriber guides any dose changes.

If you are unsure whether you meet the criteria (NHS or private) speaking to a prescriber is the quickest way to get a clear answer. Our clinical team page gives more background on who reviews your consultation. When you are ready, speak to our prescribers through a free consultation, and they will assess whether treatment is clinically appropriate for you.